Compare Novavax Inc (NVAX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs ProShares Ultra Gold ETF — how do they compare? Novavax Inc trades at $11.1 (market cap $1.82B), while ProShares Ultra Gold ETF trades at $46.17 (market cap $716.59M). The key difference: Novavax Inc is far larger — about 2.5× ProShares Ultra Gold ETF's market cap, and Novavax Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and ProShares Ultra Gold ETF for 23 Days on average.
| NVAX | UGL | |
|---|---|---|
Market Cap | $1.82B | $716.59M |
Volume | 6,198,505 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $12.56 | $85.62 |
52-Week Low | $6.22 | $42.79 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
UGL shares are trading at $44.43, down 3.29% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $45-$46 with support at $43-$44. Recent market sentiment reflects concerns about gold's performance amid rising Treasury yields and Federal Reserve policy uncertainty, creating headwinds for gold-related equities.
The stock's outlook remains challenged by macroeconomic pressures on gold prices, though potential Fed policy shifts could provide catalysts. Key risks include persistent high yields and dollar strength, while opportunities exist if inflation concerns reignite safe-haven demand. Investors should monitor Fed guidance and gold price trends for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
